Innovation Pharmaceuticals Inc (IPIX)

[MinnieM]

"To set the record straight about Krishna Menon:
by TOB Friday, 01/18/13 02:12:15 PM
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=83593955

Dr. Menon and his teams took the pemetrexed discovery studies from Princeton to the human use form now called Alimta. How one can ignore that the raw active ingredient drug is not the same as the approved modified and buffered drug is beyond rational thinking.

Again, Dr. Menon has a Ph.D. in Pharmacology from Harvard. Period. Dr. Menon is a certified Toxicologist. Period. Dr. Menon is a Doctor of Veterinary Medicine. Period. Dr. Menon was the team leader for the animal studies that took the raw compound referred to as Pemetrexed through a process of discovery to the human drug Alimta. Period. He and his team invented Alimta from the base drug Pemetrexed.

Here are 3 free articles listed in PubMed. These 3 are out of a total 34 articles listed in PubMed with Teicher and Menon as authors; both of whom were team leaders. Please also note that the most recent article is 2009, meaning none of those team members would have worked with him if he lied about any qualifications or any aspects of projects he conducted with Teicher, including their joint role in the development of Alimta. Teicher and Menon published Alimta trials up to and including Phase 3 studies. Furthermore, Menon's publications are cited in dozens and dozens of studies using his work as foundational information. None of this would be the case if allegations of exaggeration or lying about credentials had any merit whatsoever.

Here are working links to 3 of the papers.

Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasias.
Mitsiades CS, Rouleau C, Echart C, Menon K, Teicher B, Distaso M, Palumbo A, Boccadoro M, Anderson KC, Iacobelli M, Richardson PG.
Clin Cancer Res. 2009 Feb 15;15(4):1210-21.

Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human T98G glioblastoma multiforme xenografts.
Teicher BA, Menon K, Alvarez E, Galbreath E, Shih C, Faul M.
Clin Cancer Res. 2001 Mar;7(3):634-40.

Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts.
Teicher BA, Chen V, Shih C, Menon K, Forler PA, Phares VG, Amsrud T.
Clin Cancer Res. 2000 Mar;6(3):1016-23."

Here is a link to another 20 paper where Dr Menon is listed as a lead author also on the US Nation Library of Medicine National Institutes of Health

Alternatively, the scurrilous allegations seeking to discredit Dr Menon are from a discredited 'article' from a community news source which has since been removed due to it being entirely bogus. No link available as it was withdrawn.